Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Identification and validation of NFIA as a novel prognostic marker in renal cell carcinoma

de Alwis, Roger LU ; Schoch, Sarah LU ; Islam, Mazharul LU ; Möller, Christina LU ; Ljungberg, Börje and Axelson, Håkan LU (2023) In The Journal of Pathology: Clinical Research 9(4). p.261-272
Abstract

Prognostic tools are an essential component of the clinical management of patients with renal cell carcinoma (RCC). Although tumour stage and grade can provide important information, they fail to consider patient- and tumour-specific biology. In this study, we set out to find a novel molecular marker of RCC by using hepatocyte nuclear factor 4A (HNF4A), a transcription factor implicated in RCC progression and malignancy, as a blueprint. Through transcriptomic analyses, we show that the nuclear factor I A (NFIA)-driven transcription network is active in primary RCC and that higher levels of NFIA confer a survival benefit. We validate our findings using immunohistochemical staining and analysis of a 363-patient tissue microarray (TMA),... (More)

Prognostic tools are an essential component of the clinical management of patients with renal cell carcinoma (RCC). Although tumour stage and grade can provide important information, they fail to consider patient- and tumour-specific biology. In this study, we set out to find a novel molecular marker of RCC by using hepatocyte nuclear factor 4A (HNF4A), a transcription factor implicated in RCC progression and malignancy, as a blueprint. Through transcriptomic analyses, we show that the nuclear factor I A (NFIA)-driven transcription network is active in primary RCC and that higher levels of NFIA confer a survival benefit. We validate our findings using immunohistochemical staining and analysis of a 363-patient tissue microarray (TMA), showing for the first time that NFIA can independently predict poor cancer-specific survival in clear cell RCC (ccRCC) patients (hazard ratio = 0.46, 95% CI = 0.24-0.85, p value = 0.014). Furthermore, we confirm the association of HNF4A with higher grades and stages in ccRCC in our TMA cohort. We present novel data that show HNF4A protein expression does not confer favourable prognosis in papillary RCC, confirming our survival analysis with publicly available HNF4A RNA expression data. Further work is required to elucidate the functional role of NFIA in RCC as well as the testing of these markers on patient material from diverse multi-centre cohorts, to establish their value for the prognostication of RCC.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
The Journal of Pathology: Clinical Research
volume
9
issue
4
pages
261 - 272
publisher
Wiley-Blackwell
external identifiers
  • pmid:36947439
  • scopus:85150875044
ISSN
2056-4538
DOI
10.1002/cjp2.316
language
English
LU publication?
yes
additional info
© 2023 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland and John Wiley & Sons Ltd.
id
61fbf344-7a43-4c2b-90a3-7e9977bd7078
date added to LUP
2023-05-03 17:08:19
date last changed
2024-09-21 11:32:03
@article{61fbf344-7a43-4c2b-90a3-7e9977bd7078,
  abstract     = {{<p>Prognostic tools are an essential component of the clinical management of patients with renal cell carcinoma (RCC). Although tumour stage and grade can provide important information, they fail to consider patient- and tumour-specific biology. In this study, we set out to find a novel molecular marker of RCC by using hepatocyte nuclear factor 4A (HNF4A), a transcription factor implicated in RCC progression and malignancy, as a blueprint. Through transcriptomic analyses, we show that the nuclear factor I A (NFIA)-driven transcription network is active in primary RCC and that higher levels of NFIA confer a survival benefit. We validate our findings using immunohistochemical staining and analysis of a 363-patient tissue microarray (TMA), showing for the first time that NFIA can independently predict poor cancer-specific survival in clear cell RCC (ccRCC) patients (hazard ratio = 0.46, 95% CI = 0.24-0.85, p value = 0.014). Furthermore, we confirm the association of HNF4A with higher grades and stages in ccRCC in our TMA cohort. We present novel data that show HNF4A protein expression does not confer favourable prognosis in papillary RCC, confirming our survival analysis with publicly available HNF4A RNA expression data. Further work is required to elucidate the functional role of NFIA in RCC as well as the testing of these markers on patient material from diverse multi-centre cohorts, to establish their value for the prognostication of RCC.</p>}},
  author       = {{de Alwis, Roger and Schoch, Sarah and Islam, Mazharul and Möller, Christina and Ljungberg, Börje and Axelson, Håkan}},
  issn         = {{2056-4538}},
  language     = {{eng}},
  month        = {{03}},
  number       = {{4}},
  pages        = {{261--272}},
  publisher    = {{Wiley-Blackwell}},
  series       = {{The Journal of Pathology: Clinical Research}},
  title        = {{Identification and validation of NFIA as a novel prognostic marker in renal cell carcinoma}},
  url          = {{http://dx.doi.org/10.1002/cjp2.316}},
  doi          = {{10.1002/cjp2.316}},
  volume       = {{9}},
  year         = {{2023}},
}